An experimental therapy to improve skeletal growth and prevent bone loss in a mouse model overexpressing IL-6

Osteoporosis International

Volumn 25, Issue 2, 2014, Pages 681-692

  Del Fattore, A ^a   Cappariello, A ^a   Capulli, M ^b   Rucci, N ^b   Muraca, M ^a   De Benedetti, F ^a   Teti, A ^b  

^a BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

^b UNIVERSITY OF L'AQUILA   (Italy)

Author keywords

Bone loss; IL 6; Inflammatory diseases; Osteoporosis; Osteoprotegerin

Indexed keywords

ALANINE AMINOTRANSFERASE; AMYLASE; ASPARTATE AMINOTRANSFERASE; BIOLOGICAL MARKER; FC OPG; INTERLEUKIN 6; OSTEOPROTEGERIN; PARATHYROID HORMONE[1-34]; POTASSIUM; RNA; UNCLASSIFIED DRUG; BONE DENSITY CONSERVATION AGENT; INTERLEUKIN-6, MOUSE;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMYLASE BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BODY WEIGHT; BONE DEFECT; BONE GROWTH; BONE LENGTH; BONE MARROW CELL; BONE MASS; BONE TURNOVER; COLONY FORMING UNIT F; CONTROLLED STUDY; EXPERIMENTAL MUSCULOSKELETAL DISEASE; EXPERIMENTAL THERAPY; FEMALE; GENE OVEREXPRESSION; HISTOCHEMISTRY; HISTOLOGY; IN VITRO STUDY; MALE; MONONUCLEAR CELL; MORPHOMETRICS; MOUSE; NONHUMAN; OSSIFICATION; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; POTASSIUM BLOOD LEVEL; PRIMARY CELL CULTURE; PRIORITY JOURNAL; PROPHYLAXIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STUNTING; TIBIA; TRABECULAR BONE; ANIMAL; BIOSYNTHESIS; CELL CULTURE; DISEASE MODEL; DRUG COMBINATION; DRUG EFFECTS; DRUG SCREENING; GENETICS; GROWTH DISORDERS; METABOLISM; MICRO-COMPUTED TOMOGRAPHY; OSTEOPOROSIS; PATHOLOGY; PHYSIOLOGY; PROCEDURES; TRANSGENIC MOUSE;

ANIMALS; BODY WEIGHT; BONE DENSITY CONSERVATION AGENTS; CELLS, CULTURED; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; DRUG THERAPY, COMBINATION; FEMALE; GROWTH DISORDERS; INTERLEUKIN-6; MALE; MICE, TRANSGENIC; OSTEOCLASTS; OSTEOPOROSIS; OSTEOPROTEGERIN; TERIPARATIDE; X-RAY MICROTOMOGRAPHY;

EID: 84899125246     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-013-2479-2     Document Type: Article

References (41)

1. Cassidy JT, Hillman LS (1997) Abnormalities in skeletal growth in children with juvenile rheumatoid arthritis. Rheum Dis Clin N Am 23:499-522 (Pubitemid 27397118)
2. Burnham JM, Leonard MB (2004) Bone disease in pediatric rheumatologic disorders. Curr Rheumatol Rep 6:70-78
3. Lee N, Radford-Smith G, Taaffe DR (2005) Bone loss in Crohn's disease: exercise as a potential countermeasure. Inflamm Bowel Dis 11:1108-1118 (Pubitemid 41682568)
4. van Hogezand RA, Hamdy NA (2006) Skeletal morbidity in inflammatory bowel disease. Scand J Gastroenterol Suppl 243:59-64
5. Baker-LePain JC, NakamuraMC, Lane NE (2011) Effects of inflammation on bone: an update. Curr Opin Rheumatol 23:389-395
6. Via MA, Gallagher EJ, Mechanick JI (2010) Bone physiology and therapeutics in chronic critical illness. AnnN YAcad Sci 1211:85-94
7. Ansell BM, Bywaters EG (1956) Growth in Still's disease. Ann Rheum Dis 15:295-319
8. Henderson CJ, Cawkwell GD, Specker BL, Sierra RI, Wilmott RW, Campaigne BN, Lovell DJ (1997) Predictors of total body bone mineral density in non-corticosteroid-treated prepubertal children with juvenile rheumatoid arthritis. Arthritis Rheum 40:1967-1975 (Pubitemid 27494656)
9. McLean RR (2009) Proinflammatory cytokines and osteoporosis. Curr Osteoporos Rep 7:134-139
10. MacRae VE, Farquharson C, Ahmed SF (2006) The pathophysiology of the growth plate in juvenile idiopathic arthritis. Rheumatology (Oxford) 45:11-19 (Pubitemid 43033868)
11. Lien G, Selvaag AM, Flato B, Haugen M, Vinje O, Sorskaar D, Dale K, Egeland T, Førre Ø (2005) A two-year prospective controlled study of bone mass and bone turnover in children with early juvenile idiopathic arthritis. Arthritis Rheum 52:833-840 (Pubitemid 40365106)
12. De Benedetti F, Rucci N, Del Fattore A, Peruzzi B, Paro R, Longo M, Vivarelli M, Muratori F, Berni S, Ballanti P, Teti A (2006) Impaired skeletal development in interleukin-6 transgenic mice. A model for the impact of chronic inflammation in growing skeletal system. Arthritis and Rheumatism 54:3551-3563 (Pubitemid 44737167)
13. De Benedetti F, Alonzi T, Moretta A, Lazzaro D, Costa P, Poli V, Martini A, Ciliberto G, Fattori E (1997) Interleukin 6 causes growth impairment in transgenic mice through a decrease in insulin-like growth factor-I. A model for stunted growth in children with chronic inflammation. J Clin Invest 15:643-650 (Pubitemid 27097665)
14. Finkelstein JS, Wyland JJ, Lee H, Neer RM (2010) Effects of teriparatide, alendronate, or both in women with postmenopausal osteoporosis. J Clin Endocrinol Metab 95:1838-1845
15. Recker RR, Armas L (2011) The effect of antiresorptives on bone quality. Clin Orthop Relat Res 469:2207-2214
16. Mosekilde L, Tørring O, Rejnmark L (2011) Emerging anabolic treatments in osteoporosis. Curr Drug Saf 6:62-74
17. Rejnmark L, Mosekilde L (2011) New and emerging antiresorptive treatments in osteoporosis. Curr Drug Saf 6:75-88
18. Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, Elliott R, Colombero A, Elliott G, Scully S, Hsu H, Sullivan J, Hawkins N, Davy E, Capparelli C, Eli A, Qian YX, Kaufman S, Sarosi I, Shalhoub V, Senaldi G, Guo J, Delaney J, Boyle WJ (1998) Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 17:165-176 (Pubitemid 28180851)
19. Cummings SR, SanMartin J, McClung MR, Siris ES, Eastell R, Reid IR, Delmas P, Zoog HB, Austin M, Wang A, Kutilek S, Adami S, Zanchetta J, Libanati C, Siddhanti S, Christiansen C (2009) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 20:756-765
20. Kostenuik PJ, Nguyen HQ, McCabe J,Warmington KS, Kurahara C, Sun N, Chen C, Li L, Cattley RC, Van G, Scully S, Elliott R, Grisanti M, Morony S, Tan HL, Asuncion F, Li X, Ominsky MS, Stolina M, Dwyer D, Dougall WC, Hawkins N, Boyle WJ, Simonet WS, Sullivan JK (2009) Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine/human) RANKL. J Bone Miner Res 24:182-195
21. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Lüthy R, Nguyen HQ, Wooden S, Bennett L, Boone T, Shimamoto G, DeRose M, Elliott R, Colombero A, Tan HL, Trail G, Sullivan J, Davy E, Bucay N, Renshaw-Gegg L, Hughes TM, Hill D, Pattison W, Campbell P, Sander S, Van G, Tarpley J, Derby P, Lee R, Boyle WJ (1997) Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 18:309-319 (Pubitemid 27199902)
22. Morony S, Capparelli C, Lee R, Shimamoto G, Boone T, Lacey DL, Dunstan CR (1999) A chimeric form of osteoprotegerin inhibits hypercalcemia and bone resorption induced by IL-1beta, TNF-alpha, PTH, PTHrP, and 1, 25(OH)2D3. J Bone Miner Res 14:1478-1485 (Pubitemid 29416673)
23. Capparelli C, Morony S, Warmington K, Adamu S, Lacey D, Dunstan CR, Stouch B, Martin S, Kostenuik PJ (2003) Sustained antiresorptive effects after a single treatment with human recombinant osteoprotegerin (OPG): a pharmacodynamic and pharmacokinetic analysis in rats. J Bone Miner Res 5:852-858 (Pubitemid 37294968)
24. Bilezikian JP, RubinMR, Finkelstein JS (2005) Parathyroid hormone as an anabolic therapy for women and men. J Endocrinol Invest 28:41-49
25. Reeve J, Meunier PJ, Parsons JA, Bernat M, Bijvoet OL, Courpron P, Edouard C, Klenerman L, Neer RM, Renier JC, Slovik D, Vismans FJ, Potts JT Jr (1980) Anabolic effect of human parathyroid hormone fragment on trabecular bone in involutional osteoporosis: a multicentre trial. Br Med J 7:1340-1344 (Pubitemid 10124272)
26. Cusano NE, Bilezikian JP (2011) Combination antiresorptive and osteoanabolic therapy for osteoporosis: we are not there yet. Curr Med Res Opin 27:1705-1707
27. Bilezikian JP (2008) Combination anabolic and antiresorptive therapy for osteoporosis: opening the anabolic window. Curr Osteoporos Rep 6:24-30
28. Black DM, Greenspan SL, Ensrud KE, Palermo L, McGowan JA, Lang TF, Garnero P, Bouxsein ML, Bilezikian JP, Rosen CJ (2003) The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 25:1207-1215 (Pubitemid 37152030)
29. Lewiecki EM (2011) New targets for intervention in the treatment of postmenopausal osteoporosis. Nat Rev Rheumatol 7:631-638
30. Bachrach LK (2007) Consensus and controversy regarding osteoporosis in the pediatric population. Endocr Pract 13:513-520
31. Parfitt AM, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, Ott SM, Recker RR (1987) Bone histomorphometry: standardization of nomenclature, symbols, and units: report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res 2:595-610
32. Benedetti D, De Benedetti F, Meazza C, Oliveri M, Pignatti P, Vivarelli M, Alonzi T, Fattori E, Garrone S, Barreca A, Martini A (2001) Effect of IL-6 on IGF binding protein-3: a study in IL-6 transgenic mice and in patients with systemic juvenile idiopathic arthritis. Endocrinology 142:4818-4826 (Pubitemid 33022357)
33. Hoshino K, Hanyu T, Arai K, Takahashi HE (2001) Mineral density and histomorphometric assessment of bone changes in the proximal tibia early after induction of type II collagen-induced arthritis in growing and mature rats. J Bone Miner Metab 19:76- 83
34. Kitamura H, Kawata H, Takahashi F, Higuchi Y, Furuichi T, Ohkawa H (1995) Bone marrow neutrophilia and suppressed bone turnover in human interleukin-6 transgenic mice: a cellular relationship among hematopoietic cells, osteoblasts, and osteoclasts mediated by stromal cells in bone marrow. Am J Pathol 147:1682-1692
35. Sims NA, Jenkins BJ, Quinn JM, Nakamura A, Glatt M, Gillespie MT, Ernst M, Martin TJ (2004) Glycoprotein 130 regulates bone turnover and bone size by distinct downstream signaling pathways. J Clin Invest 113:379-389 (Pubitemid 38544182)
36. Vahle JL, Sato M, Long GG, Young JK, Francis PC, Engelhardt JA, Westmore MS, Linda Y, Nold JB (2002) Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human safety. Toxicol Pathol 30:312-321 (Pubitemid 34556102)
37. Samadfam R, Xia Q, Goltzman D (2007) Pretreatment with anticatabolic agents blunts but does not eliminate the skeletal anabolic response to parathyroid hormone in oophorectomized mice. Endocrinology 148:2778-2787 (Pubitemid 46984814)
38. Pierroz DD, Bonnet N, Baldock PA, Ominsky MS, Stolina M, Kostenuik PJ, Ferrari SL (2010) Are osteoclasts needed for the bone anabolic response to parathyroid hormone? A study of intermittent parathyroid hormone with denosumab or alendronate in knock-in mice expressing humanized RANKL. J Biol Chem 3(285):28164-28173
39. Letocha AD, Cintas HL, Troendle JF, Reynolds JC, Cann CE, Chernoff EJ, Hill SC, Gerber LH, Marini JC (2005) Controlled trial of pamidronate in children with types III and IV osteogenesis imperfecta confirms vertebral gains but not short-term functional improvement. J Bone Miner Res 20:977-986 (Pubitemid 40712822)
40. Speiser PW, Clarson CL, Eugster EA, Kemp SF, Radovick S, Rogol AD, Wilson TA, Pharmacy LWPES, Committee T (2005) Bisphosphonate treatment of pediatric bone disease. Pediatr Endocrinol Rev 3:87-96 (Pubitemid 43213211)
41. Jayaraman M, Karikumar K, Verma A, Modi KD (2011) Alendronate therapy in polyostotic fibrous dysplasia presenting with pathologic fracture. Am J Orthop 40:48-50